Articles On Actinogen Medical (ASX:ACW)

The Actinogen Medical Ltd (ASX: ACW) share price has been an investor’s dream of late, rising 414% in the last 3 months and 552% over the last 12 months. With a raft of good news for the biotechnology company lately, we take a closer look....

Peter Switzer sits down with the CEO and Managing Director of Actinogen Medical (ACW), Dr Steven Gourlay.

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Cogstate (ASX:CGS) has become the latest ASX health stock to gain from an FDA green light even though it is only indirectly involved – right now. Overnight the US regulator approved the first Alzheimer’s therapy since 2003 and the first dru...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

Investors will be watching for updates on Traka Resources (ASX:TKL) this week, after the gold explorer ripped higher on no news to post an RSI reading of 91. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Re...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Actinogen Medical Ltd (ASX: ACW) shares are tumbling today after the company released its quarterly activity report and strategic update this morning. At the time of writing, the Actinogen share price is sliding a whopping 17.24% to 4.8 ce...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Actinogen Medical Ltd (ASX: ACW) shares are rocketing higher today and have now gained 165% since the start of 2021. At the time of writing, the Actinogen share price is trading 23.26% higher for the day so far at 5.3 cents, up from just 2...

March got off to a rough start, with ASX small caps suffering their worst week since October and the Small Ords Index falling into the red on the year. But it got better. US punters received another stimmy cheque in the mail from President...

Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the level at which a company may have been...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Actinogen Medical CEO Dr Bill Ketelbey speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

The Actinogen Medical Ltd (ASX: ACW) share price jumped 4.5% on open this morning, after the company announced it has filed two new patent applications to strengthen and extend its intellectual property (IP) portfolio.   What does Actinoge...

Actinogen (ASX:ACW) has reveals plans for two clinical trials it will conduct next year - against MCI due to Alzheimers ... Read More The post Actinogen reveals its next clinical trial plans appeared first on Stockhead.

ASX-listed Actinogen Medical is in front of potential investors seeking a $10 million equity injection to fund a trial for its Alzheimer's drug. 

Actinogen Medical (ASX:ACW’) has announced the appointment of Mr Jeff Carter as its new chief financial officer (CFO).

A quick wrap of the key winners and losers on Tuesday, June 2. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   Code Name Price % Chg...

From the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a condition characterised by debilitating chronic daily headaches and in some cases severe vision impairment. It’s a poorly treated condi...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

With the world focused on the outcome of clinical trials for a COVID-19 vaccine, new research may add a new layer of complexity to a trial process that mainly uses male animals and male humans in the development stages for drugs. A team of...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

Who said you have to be patient to net a hefty return on an investment? There are 10 ASX small caps that tripled (gained 200 per cent or more) in a day in 2019. Stockhead recaps the lucky companies and the reason for their show-stopping per...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The 10th Annual Australian Microcap Investment Conference will be held on Tuesday 22 October 2019 over two days at the Sofitel Melbourne on Collins. The Conference is Australia’s largest and most comprehensive emerging company investment ev...

Investors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a room at the upcoming AusBiotech Invest & Partnering 2019 event in late October. The southern hemisphere’s biggest biotech investment even...

The Board of advanced Australian lithium developer Core Lithium (ASX: CXO) has announced the appointment of Malcolm McComas as a non-executive director, effective immediately. Mr McComas joins the Board as Core strengthens the organisation...

By Tim Boreham, Editor, The New Criterion When a stock is trading at a fraction of a cent, it’s usually a message for investors to abandon all hope and sell for the tax losses while they can. But ‘penny dreadful’ shares can sometimes rise...

In 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks, why they gained and where they are now.   10. AssetOwl (ASX: AO1) +225% (16 April) A fellow micro-cap gave AssetOwl a massive leg up back...

Each Monday, Stockhead recaps which stocks are heavily demanded by investors — or running hot. Stockhead uses the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price action. A reading...

It wasn’t quite a case of ‘Lazarus with a triple bypass’, but a recovery of miraculous proportions did happen in the biotech sector last week as Actinogen (ASX:ACW) jagged some remarkable efficacy results from what otherwise a bog-standard...

ShareCafePicking The One Cent Wonders That Could Become Dollar Dazzlers When a stock is trading at a fraction of a cent, it’s usually a message for investors to abandon all hope and sell for the tax losses while they can. But ‘penny drea...

What's hot Immuron Limited (ASX:IMC) Immuron closed up 66% to finish at 17.5c on $3.69 million stock traded. The reason for the rise was a new research agreement with the Naval Medical Research Centre (NMRC), Silver Spring, MD, USA. AU$5.5...

On Stockhead today: are semiconductors about to pick up again, California’s first pot cafe opens, biotech losers’ remarkable comeback, and angel investment firm Investible closes with $22m round. But first:   The day ahead Today the Austral...